1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,986 | 2,065 | 20:24 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:26 | BioInvent International: BioInvent to Present Data of BI-1808 Plus KEYTRUDA in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting | 224 | ACCESS Newswire | BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when combined... ► Artikel lesen | |
| 31.03. | BioInvent International AB Publishes Annual Report 2025 | 257 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 31, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class... ► Artikel lesen | |
| 26.03. | BioInvent International: BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis | 424 | ACCESS Newswire | BioInvent International (STO:BINV) - Achievement of the milestone triggers a payment of € 1 million LUND, SE / ACCESS Newswire / March 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)... ► Artikel lesen | |
| 24.03. | Notice to Annual General Meeting in BioInvent International AB | 302 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 24, 2026 / BioInvent International (STO:BINV) - The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual... ► Artikel lesen | |
| BIOINVENT Aktie jetzt für 0€ handeln | |||||
| 26.02. | BioInvent International AB: Year-End Report January 1 - December 31, 2025 | 364 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International (STO:BINV) - "During 2025 we sharpened our clinical focus and resource allocation to accelerate our most advanced assets, BI-1808... ► Artikel lesen | |
| 26.02. | BioInvent International: Invitation to Presentation of BioInvent's Year-End Report 2025 | 214 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report... ► Artikel lesen | |
| 23.02. | BioInvent International: BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting | 526 | ACCESS Newswire | Kate Hermans: Global life sciences executive with 25+ years of leadership across biopharma, commercial strategy, global operations, and value-creation transformations in both public and venture-backed... ► Artikel lesen | |
| 05.01. | BioInvent International: BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer | 489 | ACCESS Newswire | 24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a favorable... ► Artikel lesen | |
| 18.12.25 | BioInvent International: BioInvent to Participate in Upcoming Investor Conference | 454 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 18, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class... ► Artikel lesen | |
| 08.12.25 | BioInvent International: BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 | 377 | ACCESS Newswire | Early data indicate that BI-1206 has the potential to reset one of the main resistance mechanisms to rituximab47% of patients exhibited complete responses (CR), with an overall response rate of 80%Favorable... ► Artikel lesen | |
| 07.12.25 | BioInvent International: BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 | 620 | ACCESS Newswire | BioInvent International (STO:BINV)46% objective response rate (6 of 13 evaluable patients) and a 92% disease control rate (12 of 13) in relapsed/refractory CTCLImmune activation confirmed by CD8+ T... ► Artikel lesen | |
| 18.11.25 | BioInvent International: BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors | 516 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 18, 2025 / BioInvent International (STO:BINV):Most (78%) patients experienced disease control (stable disease), including heavily pretreated individuals with HER2-positive... ► Artikel lesen | |
| 17.11.25 | BioInvent International: EMA Positive Opinion for Orphan Drug Designation to BioInvent's BI-1808 for the Treatment of Cutaneous T-cell Lymphoma | 651 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 17, 2025 / BioInvent International AB ("BioInvent")(Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class... ► Artikel lesen | |
| 07.11.25 | BioInvent International: BioInvent's BI-1910 Data Validates TNFR2 as a Novel Immunotherapy Approach in Advanced Solid Tumors: Phase 1 Data at SITC 2025 | 441 | ACCESS Newswire | BioInvent International (STO:BINV)Twelve patients achieved stable disease, whereof five with disease control lasting over six months; this correlates with strong CD4? and CD8? memory T-cell expansionAs... ► Artikel lesen | |
| 03.11.25 | BioInvent International: BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 | 725 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class... ► Artikel lesen | |
| 03.11.25 | BioInvent International: BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025 | 640 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class... ► Artikel lesen | |
| 29.10.25 | BioInvent International AB: Interim Report January - September 2025 | 398 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 29, 2025 / BioInvent International (STO:BINV)"The third quarter of 2025 marked continued momentum for BioInvent as we decided to focus on our most advanced programs... ► Artikel lesen | |
| 27.10.25 | BioInvent International: Invitation to Presentation of BioInvent's Interim Report January - September 2025 | 322 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 27, 2025 / BioInvent International AB ("BioInvent")(Nasdaq Stockholm:BINV)(STO:BINV) invites investors, analysts and the press to a presentation of the interim report... ► Artikel lesen | |
| 20.10.25 | BioInvent International: Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors | 1.360 | ACCESS Newswire | BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors... ► Artikel lesen | |
| 13.10.25 | BioInvent International: Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025 | 456 | ACCESS Newswire | - Updated clinical data on BT-001 in combination with pembrolizumab to be presented in a poster- Tumor shrinkage observed in both injected and non-injected lesions LUND, SE / ACCESS Newswire / October... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,40 | +5,95 % | Mesoblast: Wenn aus Vision plötzlich Umsatz wird | ||
| EVOTEC | 5,650 | +0,18 % | Aktie "falsch bewertet": Wie Evotec am KI-Boom verdient | KI macht Arzneimittelforschung billiger - und schafft paradoxerweise mehr Arbeit für Evotec. Warum Berenberg die Aktie trotz operativer Schwäche klar zum Kauf empfiehlt. Die Pharmaindustrie setzt zunehmend... ► Artikel lesen | |
| BB BIOTECH | 49,750 | -1,68 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| MEDIGENE | 0,024 | -5,47 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 34,700 | -0,72 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| MODERNA | 46,800 | +1,04 % | Moderna - MRNA: Impfstoff-Aktie mit mega-starkem Comeback! | + 100 Prozent in 6 Monaten! mrRNA-Impfstoffe gegen Krebs, Grippe & RSV bei Moderna in der Pipeline! Neue Rallye trotz US-Gesundheitsminister Robert F. Kennedy? Moderna (MRNA) - ISIN US60770K1079 Rückblick:... ► Artikel lesen | |
| PAION | 0,047 | -25,00 % | PAION AG: Schwächesignal im Fokus der Analyse | ||
| VALNEVA | 2,628 | -0,90 % | Valneva sendet Krisensignal: Warum Sie jetzt genau hinschauen sollten - Verpassen Sie das nicht | ||
| AMGEN | 295,15 | -0,66 % | AMGEN INC - Stabilität als strategische Chance | ||
| EPIGENOMICS | 0,920 | 0,00 % | PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| NOVAVAX | 7,270 | -1,09 % | H.C. Wainwright reiterates Novavax stock rating on vaccine study | ||
| BIOGEN | 158,60 | +1,91 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| BIOFRONTERA | 2,460 | -5,75 % | PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Biofrontera... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,830 | +1,80 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma gibt Veränderung im Vorstand bekannt | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Personalie
Heidelberg Pharma gibt Veränderung im Vorstand bekannt
17.04.2026 / 09:38 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| ILLUMINA | 112,00 | -0,62 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen |
BIOINVENT INTERNATIONAL AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,016 (+0,80 %) liegt der Kurs bei 2,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOINVENT INTERNATIONAL AB finden Sie auf Wallstreet Online.